Filtered By:
Countries: Finland Health
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 173 results found since Jan 2013.
Long-term outcomes of mechanical versus biological valve prosthesis in native mitral valve infective endocarditis
Conclusion. The use of mechanical mitral valve prosthesis is associated with lower long-term mortality compared to the biological prosthesis in non-elder native mitral valve infective endocarditis patients. The routine choice of biological mitral valve prostheses for this patient group is not supported by the results.PMID:35652503 | DOI:10.1080/14017431.2022.2079712
Source: Scandinavian Cardiovascular Journal - June 2, 2022 Category: Cardiology Authors: Markus Malmberg Vesa Anttila P äivi Rautava Jarmo Gunn Ville Kyt ö Source Type: research
O-003 CLEVER: clinical evaluation of WEB 17 device in intracranial aneurysms. safety results for ruptured and unruptured aneurysm at 30 days
ConclusionThese results show good safety profile at 1 month, with low rate of neurological or neurovascular event with permanent deficit and no mortality at 30 days. These data confirm the safety of WEB use in intracranial aneurysm treatment, unruptured as well as ruptured, and are consistent with the results published up to date.Disclosures L. Spelle: 2; C; Microvention, Medtronic, Phenox, Stryker, Balt. C. Cognard: None. I. Szikora: None. V. Costalat: None. F. Wodarg: None. D. Herbreteau: None. S. Fischer: None. M. Möhlenbruch: None. C. Papagiannaki: None. J. Klisch: None. R. Rautio: None. J. Numminen: None. A. B...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Spelle, L., Cognard, C., Szikora, I., Costalat, V., Wodarg, F., Herbreteau, D., Fischer, S., Möhlenbruch, M., Papagiannaki, C., Klisch, J., Rautio, R., Numminen, J., Berlis, A., Downer, J., Bester, M., Velasco, S., Liebig, T., Byrne, J., Pierot, L Tags: SNIS 19th annual meeting oral abstracts Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Decreasing national trends in diabetic complications hide regional differences: a prospective population-based study using health care registers in Finland
Conclusions. The decrease in the incidence of first cardiovascular events among patients with diabetes continued from 2010 to 2017 in Finland. However, the declining national incidence rates hide regional differences which should be a target for improvement.PMID:37614115 | DOI:10.1080/14017431.2023.2247190
Source: Scandinavian Cardiovascular Journal - August 24, 2023 Category: Cardiology Authors: Klas Winell Martti Arffman Veikko Salomaa Source Type: research
Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population – clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - July 1, 2013 Category: Hematology Authors: M Puurunen, P Salo, S Engelbarth, K Javela, M Perola Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population - clinical picture.
CONCLUSION: In Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening. This article is protected by copyright. All rights reserved.
PMID: 23910795 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 3, 2013 Category: Hematology Authors: Puurunen M, Salo P, Engelbarth S, Javela K, Perola M Tags: J Thromb Haemost Source Type: research
Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation, p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.
Source: Journal of Thrombosis and Haemostasis - October 10, 2013 Category: Hematology Authors: M. Puurunen, P. Salo, S. Engelbarth, K. Javela, M. Perola Tags: Original Article Source Type: research
